
Annual report 2021
added 12-23-2023
Burning Rock Biotech Limited Net Income 2011-2026 | BNR
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Burning Rock Biotech Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -797 M | -407 M | -169 M | -177 M | -131 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -131 M | -797 M | -336 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
1.21 B | $ 115.48 | 0.82 % | $ 35.1 B | ||
|
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M | ||
|
Biodesix
BDSX
|
-42.9 M | $ 15.07 | 2.1 % | $ 1.95 B | ||
|
Aspira Women's Health
AWH
|
-12.8 M | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
-46.9 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Check-Cap Ltd.
CHEK
|
-25.1 M | - | - | $ 9.42 M | ||
|
Castle Biosciences
CSTL
|
18.2 M | $ 24.84 | -0.84 % | $ 690 M | ||
|
DarioHealth Corp.
DRIO
|
-41.7 M | $ 8.4 | 3.7 % | $ 33.5 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M | ||
|
BioNano Genomics
BNGO
|
-26.4 M | $ 1.2 | 0.84 % | $ 6.53 M | ||
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M | ||
|
Charles River Laboratories International
CRL
|
-144 M | $ 173.89 | -0.58 % | $ 8.62 B | ||
|
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | ||
|
DexCom
DXCM
|
836 M | $ 62.22 | -0.24 % | $ 24.3 B | ||
|
Fulgent Genetics
FLGT
|
-42.7 M | $ 16.82 | 2.31 % | $ 509 M | ||
|
Biomerica
BMRA
|
-4.97 M | $ 2.17 | -0.91 % | $ 4.98 M | ||
|
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | ||
|
Celcuity
CELC
|
-177 M | $ 112.63 | -0.27 % | $ 5.27 B | ||
|
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
-208 M | - | - | $ 19.8 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | ||
|
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
992 M | $ 198.02 | 0.17 % | $ 22 B | ||
|
Guardant Health
GH
|
-416 M | $ 93.83 | 2.94 % | $ 11.8 B | ||
|
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
234 M | $ 76.1 | 0.53 % | $ 5.14 B | ||
|
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | ||
|
Medpace Holdings
MEDP
|
451 M | $ 498.34 | 1.81 % | $ 14.4 B | ||
|
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
24.6 M | $ 1.96 | 5.82 % | $ 8.67 M | ||
|
Mettler-Toledo International
MTD
|
869 M | $ 1 259.94 | -1.11 % | $ 26 B | ||
|
ICON Public Limited Company
ICLR
|
791 M | $ 114.19 | 2.49 % | $ 9.42 B | ||
|
IDEXX Laboratories
IDXX
|
1.06 B | $ 569.55 | 0.87 % | $ 45.8 B | ||
|
Neogen Corporation
NEOG
|
-1.09 B | $ 9.41 | 0.21 % | $ 2.04 B | ||
|
Illumina
ILMN
|
-1.22 B | $ 127.38 | 0.59 % | $ 20.3 B | ||
|
IQVIA Holdings
IQV
|
1.36 B | $ 173.26 | 0.5 % | $ 29.8 B | ||
|
Pacific Biosciences of California
PACB
|
-546 M | $ 1.34 | -0.74 % | $ 402 M | ||
|
Koninklijke Philips N.V.
PHG
|
3.32 B | $ 27.11 | -0.66 % | $ 20 B | ||
|
QIAGEN N.V.
QGEN
|
425 M | - | - | $ 10.6 B | ||
|
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | ||
|
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
876 M | $ 273.72 | 0.36 % | $ 22.8 B | ||
|
Myriad Genetics
MYGN
|
-366 M | $ 4.75 | 3.49 % | $ 440 M | ||
|
Sotera Health Company
SHC
|
77.9 M | $ 14.96 | 0.61 % | $ 4.25 B | ||
|
NeoGenomics
NEO
|
-108 M | $ 8.0 | 3.23 % | $ 1.02 B | ||
|
National Research Corporation
NRC
|
11.6 M | $ 17.16 | -1.04 % | $ 384 M |